Abstract:P21-activated kinase 4 (PAK4) is a serine/threonine protein kinase, which is associated with many cancer diseases, and thus being considered as a potential drug target. In this study, three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking and molecular dynamics (MD) simulations were performed to explore the structure-activity relationship of a series of pyrropyrazole PAK4 inhibitors. The statistical parameters of comparative molecular field analysis (CoMFA, Q2 = 0.837, R2 = 0.990, and R2pred = 0.967) and comparative molecular similarity indices analysis (CoMSIA, Q2 = 0.720, R2 = 0.972, and R2pred = 0.946) were obtained from 3D-QSAR model, which exhibited good predictive ability and significant statistical reliability. The binding mode of PAK4 with its inhibitors was obtained through molecular docking study, which indicated that the residues of GLU396, LEU398, LYS350, and ASP458 were important for activity. Molecular mechanics generalized born surface area (MM-GBSA) method was performed to calculate the binding free energy, which indicated that the coulomb, lipophilic and van der Waals (vdW) interactions made major contributions to the binding affinity. Furthermore, through 100 ns MD simulations, we obtained the key amino acid residues and the types of interactions they participated in. Based on the constructed 3D-QSAR model, some novel pyrropyrazole derivatives targeting PAK4 were designed with improved predicted activities. Pharmacokinetic and toxicity predictions of the designed PAK4 inhibitors were obtained by the pkCSM, indicating these compounds had better absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. Above research provided a valuable insight for developing novel and effective pyrropyrazole compounds targeting PAK4.Communicated by Ramaswamy H. SarmaThe 3D-QSAR on pyrropyrazole PAK4 inhibitors was studied for the first time and the constructed 3D-QSAR model exhibited good predictive ability and significant statistical reliability.Molecular docking and molecular dynamics simulations were performed to obtain the binding mechanism, and the binding free energy was calculated by MM-GBSA method.Based on the CoMFA and CoMSIA models, a series of pyrropyrazole derivatives with potential better bioactivities were designed.ADMET properties of the newly designed PAK4 inhibitors were predicted, and these inhibitors exhibited better ADMET properties. three-dimensional quantitative structure-activity relationshipabsorption, distribution, metabolism, excretion, toxicitycomputer-aided drug designcomparative molecular field analysiscomparative molecular similarity indices analysisF-statistic valueshydrogen bond acceptorhydrogen bond donorlimited memory Broyden Fletcher Goldfarb Shannoleave one outmaximum common substructuremolecular dynamicsmolecular mechanics generalized-born surface areanormal pressure temperatureoptimal number of componentspartial least squarecross-validated correlation coefficient; R2, noncross-validated correlation coefficient; R2predictive correlation coefficientroot-mean-square deviationroot mean square errorstandard error of estimatesimple point chargestandard deviation and coefficientvan der WaalseXtended electron distribution.

In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

3D-QSAR, Docking, and Molecular Dynamics Simulations Studies on Quinazoline Derivatives As PAK4 Inhibitors

Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation

Synthesis and biological evaluation of 7H-pyrrolo [2,3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors

The Inhibitory Mechanism of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as Inhibitors of P21-Activated Kinase 4 through Molecular Dynamics Simulation

Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4-(4-methylpiperazin-1-yl)phenyl scaffold as potential antitumor agents

Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity

3D-QSAR and Molecular Docking Studies of ATP-competitive Akt Inhibitors with the Scaffold 4-(Piperazin-1-yl)pyrimidine

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.

Molecular docking-based 3D-QSAR studies of pyrrolo[3,4-c]pyrazole derivatives as Aurora-A inhibitors

Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular docking and molecular dynamics

3D-QSAR and Docking Studies of 3-Pyridine Heterocyclic Derivatives As Potent PI3K/mTOR Inhibitors

Study On The Interactions Of Pyrimidine Derivatives With Fak By 3d-Qsar, Molecular Docking And Molecular Dynamics Simulation

3D-QSAR and Surflex-dock Study of Pyrimidine Scaffold Compounds As Dual PI3K/mTOR Inhibitors

3D-QSAR Study for Pyridine Heterocyclic Ring PI3K Inhibitor as Anti-renal Cancer Drug

Design, Synthesis, Structure-Activity Relationships Study and X-ray Crystallography of 3-Substituted-indolin-2-one-5-carboxamide Derivatives As PAK4 Inhibitors.